Navigation Links
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
Date:6/7/2009

Improvements in Systolic Blood Pressure and Triglycerides Also Observed

NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY), and Alkermes, Inc. (Nasdaq: ALKS) today announced long-term, interim results from the DURATION-1 study that showed sustained glucose control with weight loss, as well as improvements in systolic blood pressure and triglycerides, through two years of treatment with exenatide once weekly, an investigational therapy for type 2 diabetes. These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans. A New Drug Application (NDA) for exenatide once weekly was recently submitted to the U.S. Food and Drug Administration.

In the controlled portion of the open-label study, patients received exenatide once weekly or BYETTA(R) (exenatide) injection for 30 weeks, followed by 74 weeks of treatment with exenatide once weekly for all patients during an open-ended assessment period. Significant reductions in A1C of 1.7 percent and fasting plasma glucose (FPG) of 40 mg/dL were maintained after two years of treatment. Sixty-five percent of patients achieved an A1C of 7 percent or less. A1C of less than 7 percent is the target for good glucose control as recommended by the ADA. Body weight was significantly reduced, with patients losing an average of 5.8 pounds. Serum lipid profiles were significantly improved, and there was a significant reduction in systolic blood pressure (SBP).

"These two-year DURATION-1 data showed that maintenance of steady state concentrations of exenatide may res
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
2. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
3. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
4. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
5. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
6. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
7. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
8. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
9. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 /PRNewswire-USNewswire/ ... remote-controlled catheter (MARC) which could allow physicians to see ... stroke may hold promise, according to study authors who ... Surgery (SNIS) 11 th Annual Meeting in ... findings stand to advance the field of neurointervention, a ...
(Date:7/29/2014)... NASHVILLE, Tenn. and NEW YORK ... and member of the executive management team of Caremark ... of PBM365 Media ( www.pbm365.com ).  PBM365 is the ... and unbiased reporting, insight, analysis and opinion on ... PBM365 will provide insightful and timely coverage of, ...
(Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Drew Crawford Announces Launch of PBM365 Media 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
(Date:7/29/2014)... (GSA) and the National Center for Creative Aging ... University as the 2014 recipient of the Gene D. ... award recognizes and honors the seminal work of Gene ... and aging shifted the conceptual focus from a problem ... individuals to approach longevity asking what wonders can be ...
(Date:7/29/2014)... boys with fragile X syndrome tend to decline ... of the inherited disorder to date has found. ... social and practical skills, including communication, socialization, and ... dressed. In this study, socialization emerged as a ... that it did not decline as much as ...
(Date:7/29/2014)... More Zeppelin than Zen, the Rock Spa® at Seminole Hard ... complete renovation and, upon its re-opening in the fall, will ... , The Rock Spa® will include an all-new hair and ... hair and nail stylists. Both part time and full time ... given full medical and health benefits, a rare perk in ...
(Date:7/29/2014)... Society of America (GSA) the nation,s largest ... has chosen Laura N. Gitlin, PhD, of the Johns ... 2014 recipient of the M. Powell Lawton Award. ... gerontology that has led to an innovation in gerontological ... barriers, or a public policy change that has led ...
(Date:7/29/2014)... truBrain has created a solution for ... drinks. Think Drinks , available today on Indiegogo, ... conditions for memory, complex reasoning and sustained energy while ... $50,000 over the course of the 30-day campaign. , ... have compounding effects over time when used as a ...
Breaking Medicine News(10 mins):Health News:Charon to receive 2014 Gene D. Cohen Award 2Health News:Socialization relative strength in fragile X longitudinal study 2Health News:Rock Spa® at Seminole Hard Rock Hotel & Casino Tampa Prepares for Expansion 2Health News:Gitlin earns GSA's 2014 M. Powell Lawton Award 2Health News:Focus- and Productivity-Enhancing Beverage Launches Crowdfunding Campaign on Indiegogo 2
... The American College of Radiology (ACR) and Society of ... Obstetricians and Gynecologists, (ACOG) recommendations that women begin getting ... now correspond with those of the American Cancer Society, ... Breast Disease (ASBD) and many other major medical associations ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) -- ... disease as a major health threat, fearing its onset nearly ... Germany, Poland, Spain and the United States, the poll also ... to visit a doctor if they or a loved one ...
... HealthDay Reporter , WEDNESDAY, July 20 (HealthDay News) ... players can quantify the force of impact, offering new insight ... collisions may eventually help manufacturers design helmets that are more ... the University of Michigan and lead author of a new ...
... (HealthDay News) -- Premature infants are at greater risk ... hyperactivity and depression, a new study suggests. These ... affecting cortical development as well as neural connectivity, said ... Although "preemies" are at risk for these injuries, the ...
... gene-based test to distinguish harmless from precancerous pancreatic cysts. ... needless surgery to remove the harmless variety. A ... 20 issue of Science Translational Medicine . ... more than a million patients each year, most of ...
... a special fascination for Marlene Zuk , world-class evolutionary ... offer us, she says, a way to understand living things ... "People have strong feelings about insects, and most of those ... at the University of California, Riverside. "But insects let ...
Cached Medicine News:Health News:ACR, SBI support updated ACOG recommendations that women begin annual mammograms at age 40 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 2Health News:International Poll Shows Many Fear Alzheimer's as Much as Cancer 3Health News:High-Tech Football Helmets Gauge Force of Collision 2Health News:Preemies at Risk for Psychiatric Disorders as Teens, Study Contends 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 2Health News:Benign or cancerous? Gene test predicts cancer potential in pancreatic cysts 3Health News:'Sex on Six Legs' is focus of UC Riverside biologist's book 2Health News:'Sex on Six Legs' is focus of UC Riverside biologist's book 3Health News:'Sex on Six Legs' is focus of UC Riverside biologist's book 4
Colloidal Gold Conjugated, Protein A - 12 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Conjugated, Protein G - 12 OD...
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: